Authors: Zhang JL, Tong AL, Feng YL, Zhao DC, Zhong L, Gao YJ, Song YL, Zhang TP, Li M, Chen YJ.
DOI: 10.3389/fendo.2025.1685806
Abstract Summary
Patients with insulinoma show elevated levels of LEAP2, a newly identified hormone that counteracts ghrelin. This study found LEAP2 correlates with both hyperinsulinemia and obesity in insulinoma patients, and is expressed directly in tumor tissue—suggesting it may play a key role in the metabolic complications of this condition.
Why Brain? 🧠
Elevated LEAP2 levels in insulinoma patients correlate with hyperinsulinemia and obesity, with tumor tissue expressing this ghrelin antagonist, revealing potential metabolic mechanisms.
License: CC BY.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
